Sands Capital Ventures
ACRV icon

Sands Capital Ventures’s Acrivon Therapeutics ACRV Stock Holding History

Sands Capital Ventures’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.69M Hold
2,289,271
– – 0.68% 22
2026
Q2 		$4.07M Buy
2,289,271
+166,666
+8% +$283K 0.66% 23
2026
Q1 		$2.95M Hold
2,122,605
– – 0.7% 19
2025
Q4 		$5.12M Hold
2,122,605
– – 0.99% 16
2025
Q3 		$3.84M Hold
2,122,605
– – 0.84% 17
2025
Q2 		$2.53M Hold
2,122,605
– – 0.5% 17
2025
Q1 		$4.31M Hold
2,122,605
– – 1.05% 13
2024
Q4 		$12.8M Hold
2,122,605
– – 2.78% 8
2024
Q3 		$14.9M Hold
2,122,605
– – 4.18% 5
2024
Q2 		$12.3M Buy
2,122,605
+470,000
+28% +$3.79M 4.12% 6
2024
Q1 		$11.8M Hold
1,652,605
– – 2.85% 8
2023
Q4 		$8.13M Hold
1,652,605
– – 2.26% 9
2023
Q3 		$15.8M Hold
1,652,605
– – 4.67% 9
2023
Q2 		$21.4M Hold
1,652,605
– – 6.34% 7
2023
Q1 		$21M Hold
1,652,605
– – 5.18% 8
2022
Q4 		$19M Buy
+1,652,605
New +$21M 5.21% 7

Other funds holding ACRV

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Empowered Funds
Empowered Funds Havertown, Pennsylvania $21.7B AUM 41.23% 1-Year Est. Return

Sands Capital Ventures's ACRV Position: Q3 2026 in Review

Sands Capital Ventures held its Acrivon Therapeutics (ACRV) position steady in Q3 2026 at 2,289,271 shares worth $4.69M. The position accounts for 0.68% of the portfolio, ranked #22.

Sands Capital Ventures first reported a position in ACRV in Q4 2022 and has held it in 16 quarters since. The position peaked at $21.4M in Q2 2023. 33 funds tracked by Wall St. Rank hold ACRV as of Q3 2026.

  • Sands Capital Ventures held 2,289,271 shares of Acrivon Therapeutics worth $4.69M as of Q3 2026.
  • Sands Capital Ventures left its Acrivon Therapeutics share count unchanged in Q3 2026.
  • Acrivon Therapeutics made up 0.68% of Sands Capital Ventures's portfolio in Q3 2026, its #22 holding.
  • Sands Capital Ventures first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 16 quarters since.
  • Sands Capital Ventures's Acrivon Therapeutics position peaked at $21.4M in Q2 2023.
  • 33 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2026.

Based on Sands Capital Ventures's 13F filing for Q3 2026, filed 13 Nov 2026.